Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects

To describe the clinical syndrome of 4 new patients with seizure-related 6 homolog like 2 antibodies (SEZ6L2-abs), study the antibody characteristics, and evaluate their effects on neuronal cultures. SEZ6L2-abs were initially identified in serum and CSF of a patient with cerebellar ataxia by immunoh...

Full description

Saved in:
Bibliographic Details
Published inNeurology : neuroimmunology & neuroinflammation Vol. 8; no. 1; p. e916
Main Authors Landa, Jon, Guasp, Mar, Petit-Pedrol, Mar, Martínez-Hernández, Eugenia, Planagumà, Jesús, Saiz, Albert, Ruiz-García, Raquel, García-Fernández, Lorena, Verschuuren, Jan, Saunders-Pullman, Rachel, Ramirez-Gómez, Liliana, Geschwind, Michael D., Dalmau, Josep, Sabater, Lidia, Graus, Francesc
Format Journal Article
LanguageEnglish
Published United States American Academy of Neurology 01.01.2021
Lippincott Williams & Wilkins
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To describe the clinical syndrome of 4 new patients with seizure-related 6 homolog like 2 antibodies (SEZ6L2-abs), study the antibody characteristics, and evaluate their effects on neuronal cultures. SEZ6L2-abs were initially identified in serum and CSF of a patient with cerebellar ataxia by immunohistochemistry on rat brain sections and immunoprecipitation from rat cerebellar neurons. We used a cell-based assay (CBA) of HEK293 cells transfected with to test the serum of 95 patients with unclassified neuropil antibodies, 331 with different neurologic disorders, and 10 healthy subjects. Additional studies included characterization of immunoglobulin G (IgG) subclasses and the effects of SEZ6L2-abs on cultures of rat hippocampal neurons. In addition to the index patient, SEZ6L2-abs were identified by CBA in 3/95 patients with unclassified neuropil antibodies but in none of the 341 controls. The median age of the 4 patients was 62 years (range: 54-69 years), and 2 were female. Patients presented with subacute gait ataxia, dysarthria, and mild extrapyramidal symptoms. Initial brain MRI was normal, and CSF pleocytosis was found in only 1 patient. None improved with immunotherapy. SEZ6L2-abs recognized conformational epitopes. IgG4 SEZ6L2-abs were found in all 4 patients, and it was the predominant subclass in 2. SEZ6L2-abs did not alter the number of total or synaptic SEZ6L2 or the AMPA glutamate receptor 1 (GluA1) clusters on the surface of hippocampal neurons. SEZ6L2-abs associate with a subacute cerebellar syndrome with frequent extrapyramidal symptoms. The potential pathogenic effect of the antibodies is not mediated by internalization of the antigen.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
These authors contributed equally to this work.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
These authors share seniority.
The Article Processing Charge was funded by the authors.
ISSN:2332-7812
2332-7812
DOI:10.1212/NXI.0000000000000916